Xutian Jing
井绪天
Xutian Jing is a partner at 5Y Capital (五源资本), promoted in September 2025 after rising through the ranks from executive director to managing director . He joined the firm in 2016, having previously worked as a management consultant at IMS Health serving global pharmaceutical companies and top PE firms after graduating from the University of Pennsylvania . His investment focus sits at the intersection of information technology and biotechnology—what he has called the ITBT sector—where he sees potential for a new generation of pharma companies with strong cash-generation capabilities . Among his notable deals, he led or participated in investments in XtalPi (晶泰科技), MedSci Healthcare's nearly 2 billion yuan Series E1, Abogen Biosciences' $300 million Series C+, and Deepwise Technology's Series B+ . In a 暗涌Waves profile marking his promotion, he was described asking a founder a physics question on a night flight: "Is the world predetermined?" .
AI-generated — may contain errors, please verify.
Coverage
5Y News | Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange listing!
METiS Pharmaceuticals, the world's first publicly listed AI-driven drug delivery company, goes public, ushering in a new era for biopharmaceuticals.
5Y News | Xunming Life Sciences Closes Tens of Millions of Dollars in Series A+ Funding
Accelerating the construction of next-generation Tech-Bio agent infrastructure.
Is the "ChatGPT Moment" for Bio-Manufacturing Here? | 5Y Talk
From the industry's ups and downs to the inflection point brought by AI, from a "lab crayfish" to the "ChatGPT moment" of bio-manufacturing.
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
January, Emergence, and Prologue | 5Y News Monthly
The big news from last month.
Five Sources Capital Promotes Its First Post-90s Partner
How Do VCs Grow New Capabilities?
5Y News | Xuanming Life Sciences Closes Tens of Millions of Dollars in Series A Funding
Accelerating the intelligent design of antibodies and the development of innovative pipelines.
Compile Uncertainty into Answers | 5Y News Monthly
The big news from last month.
The World Is Bigger Than the Logic Right in Front of You | 5Y News Monthly
The big news from last month.
5Y News｜Syneron Bio Enters Strategic Partnership with AstraZeneca
Continue to track technological innovation in the biopharma space.
Miracles Come from Perseverance | 5Y News Monthly
The big news from last month.
Congratulations to Taimei Medical Technology on its successful listing on the Hong Kong Stock Exchange! | 5Y News
Empowering the global pharmaceutical R&D industry.
Congratulations to XtalPi on its successful listing on the Hong Kong Stock Exchange! | 5Y News
"AI + Robotics" builds the first 18C-listed stock, constructing new R&D infrastructure for future industries.
Change Begins with What You See | 5Y News Monthly
The big news from last month.
The beginning of a miracle often lies within the thing itself | 5Y News Monthly
The big news from last month.
Success is rarely replicable; what matters is finding your own path | 5Y View x Bota Bio x METiS Pharmaceuticals
Cross-disciplinary methodology for entrepreneurship.
Pressing Onward, Into the Unknown | 5Y News Monthly
The big news from last month.
February: Returning to Our Imagination of the World | 5Y News Monthly
The big news from last month.
Finding True Non-Consensus: Time as a Moat | 5Y Capital Partner Meeting Recap
Focus only on things that are absolutely meaningful.
Medicine Is the Science of Uncertainty and the Art of Possibility | 5Y Talk × Sihui Ma Xuguang
Illness is part of being human, and humans are part of society.
5Y News | Portfolio Company PAM2L Biotechnologies Closes Pre-A Round of Over 100 Million RMB
Leveraging synthetic biology and machine learning as dual engines to drive bio-based materials and product development.
Congratulations to MedSci Healthcare Successfully Listing on the Hong Kong Stock Exchange | 5Y News
Transforming China's healthcare industry.
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
From Tech to Business: New Possibilities Brought by ITBT | 5Y Talk
We spoke with five entrepreneurs about their progress and breakthroughs.
5Y News | Axbio Closes Nearly $100M Series B Funding Round
Make faster, more accessible, ultra-low-cost sequencing products available to the life sciences and healthcare industries.
June, Vitality | 5Y News Monthly
The big news from last month.
MaHui | Source Code Capital's Xingchen Zhang Named to Cyzone's 40 Under 40 Investors List
"Finding tech founders full of conviction"
5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
5Y News | Limmuno Biotech Closes Nearly RMB 100 Million Angel Round
Immunometabolic Reprogramming + AI-Powered Computation for Innovative Cancer Immunotherapy
5Y News | AI+RNA Startup ReviR Therapeutics Closes Tens of Millions of Dollars in Pre-A Round
Using AI algorithms and gene technology to drive targeted RNA drug development.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
5Y News | PAM2L Biotechnologies Completes Angel Round, Launching New Chapter in Synthetic Biomaterial R&D
5Y Capital continues to seek out and support technology innovation companies.
5Y News | Abogen Biosciences Completes $300 Million Series C+ Round
Contribute to the innovation-driven development of the biopharmaceutical industry.
5Y News | "中科国生" Raises Tens of Millions of RMB in Angel Round to Develop and Promote Functional Bio-based New Materials
Transforming lives with biomass.
5Y News | Signet Therapeutics Raises Nearly $10 Million to Power AI-Enabled Innovative Targeted Drug Development Through Disease Modeling Platform
Advancing pharmaceutical innovation in China.
5Y News | AI Pharmaceutical Industrial Platform Hourstec Closes Nearly $10 Million Pre-A Round
5Y Capital continues to track applications of computational science in life and health sciences.
September, When Hope Will Break Through Like the Sun | 5Y News Monthly
The big news from last month.
When a group of genuine, smart, and interesting young tech people live together for five days and four nights | 3Sigma Bootcamp documentary
The few who exist beyond 3Sigma — kindred spirits on the entrepreneurial road.
5Y Capital Wins Multiple Awards Including "2021 China Venture Capital Firm of the Year" | 5Y News
Continuously searching for scarce founders.
5Y News | Galixir Completes New Strategic Funding Round, Continues Advancing Drug R&D Pipeline
5Y Capital continues to watch for opportunities where information technology can be applied in healthcare and medicine.
5Y News | Synthetic Biology Company Bota Bio Raises Over $100 Million to Accelerate Efficient Design and Scaled Production of Bio-based Products
5Y Capital continues to pay close attention to emerging technologies at the intersection of information science and life sciences.
5Y News | Neox Biotech Completes Tens of Millions of Dollars in Series A+ Funding to Advance Innovative Drug Pipeline
5Y Capital continues to provide support.
The Best Is Always Ahead | 5Y News Monthly
Happy Labor Day!
5Y Capital's Xu Tian Jing: Why We're Bullish on Digital Pharmaceutical R&D | 5Y Talk
The ITBT track has a promising future ahead.
April, When All Things Grow | 5Y News Monthly
Looking back at last month's big events, ready to take on Q2 with full confidence.
5Y News | AI Ultrasound Company Deepwise Technology Closes Nearly 100 Million Yuan Series B+ Round
The combination of AI software and portable ultrasound is set to transform the healthcare services industry.
5Y News｜Neox Biotech Completes $30 Million Series A Round, 5Y Capital Continues Support
Exploring the most cutting-edge drug modalities.
5Y News | Galixir Announces Completion of Tens of Millions of USD in Funding, with Continued Backing from 5Y Capital
Breaking the Bottleneck in New Drug R&D with "AI+"
5Y News｜Vivace Therapeutics Announces Completion of Angel Round Raising Tens of Millions of RMB
Huanyi Bio announced the completion of an angel funding round of tens of millions of RMB, led by 5Y Capital.
5Y News | MedSci Healthcare Announces Nearly 2 Billion Yuan Series E1 Funding Round
5Y Capital will continue to focus on how technological innovation drives efficiency gains and paradigm shifts in China's healthcare services sector.
5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
Morning Star Portfolio Company "Nuoxin Chuanglian" Closes New 200 Million Yuan Funding Round | Light Moments
Nexon Healthcare, which builds digital bridges between pharmaceutical companies and doctors, has raised 200 million RMB in a new funding round.
Morningside-backed XtalPi raises over $300 million in new funding | Light Moments
5Y Capital has long been bullish on the application of computational science in the life sciences, hoping that the convergence of IT and biotechnology will soon usher human health into a new era.
Morningside-backed LifeTech Scientific raises over RMB 1.2 billion in new funding round | Light Moments
China's new drug R&D is undergoing a "Cambrian explosion." The industry's underlying infrastructure for pharmaceutical innovation is one of the core sectors we're tracking in healthcare.
5Y Capital's Xutian Jing: ITBT Sector Has a Promising Future, Poised to Produce a New Breed of Pharma Companies with Strong Cash-Generation Capabilities | Light View
ITBT is a long game, but when it succeeds, its contribution to human society is immense.
The Collision of AI and Pharmaceuticals: Galaxy Pharma Tech Raises Nearly $10 Million in Funding | Light Moments
Galixir announced the completion of a nearly $10 million Pre-A funding round. The round was co-led by Source Code Capital and DCM, with 5Y Capital participating as a follow-on investor. Gaorong Capital, the lead investor in the company's angel round, continued to increase its stake.
